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ABSTRACT: The presence of biomarkers characteristic for
Alzheimer’s disease in the retina is a controversial topic. Raman
spectroscopy offers information on the biochemical composition of
tissues. Thus, it could give valuable insight into the diagnostic
value of retinal analysis. Within the present study, retinas of a
double transgenic mouse model, that expresses a chimeric mouse/
human amyloid precursor protein and a mutant form of human
presenilin 1, and corresponding control group were subjected to ex
vivo Raman imaging. The Raman data recorded on cross sections
of whole eyes highlight the layered structure of the retina in a label-
free manner. Based on the Raman information obtained from en
face mounted retina samples, a discrimination between healthy and
Alzheimer’s disease retinal tissue can be done with an accuracy of
85.9%. For this a partial least squares-linear discriminant analysis was applied. Therefore, although no macromolecular changes in
form of, i.e., amyloid beta plaques, can be noticed based on Raman spectroscopy, subtle biochemical changes happening in the retina
could lead to Alzheimer’s disease identification.
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■ INTRODUCTION
One of the most controversial discussion topics on Alzheimer′s
disease (AD) research is whether specific biomarkers can be
detected noninvasively in the retina.1−3 The eye is part of the
cerebral nervous system, and it is the only region that can be
imaged in vivo noninvasively by optical methods. If the AD
pathogenesis would manifest itself in the retina at early stages
of the disease and these biochemical changes could be
detected, valuable insights that are not accessible at the
moment would be gained. Optical coherence tomography
(OCT) is the method of choice for performing ophthalmologic
investigations in vivo. This method gives morphological
information on the layered structure of the retina. Based on
the OCT images, medical conditions of the eye that involve
structural changes of the retinal layers can be diagnosed.
However, it is believed that these changes are preceded by
subtle biochemical modifications of the retina that cannot be
detected by OCT. The identification of the amyloid β plaques
and phosphorylated tau tangles in ex vivo retina samples has
been reported in mouse models4−7 as well as human eyes.4,6,8
Nevertheless, there are also studies that report on the absence
of these biomarkers at the retina level and question the
diagnostic value of this approach.9−11 The described detection
methods are mostly based on labels, such as curcumin,
Thioflavin-S, or amyloid β antibody. This requires that the
investigated sample is subjected to laborious preparation steps,
and a frequent concern is the questionable specificity of many
of the labels used in these studies.
Raman spectroscopy is known to provide label-free
molecular specific fingerprint information, and thus, it can
monitor subtle biochemical changes on the cellular level. It is
often applied to identify pathogens or in imaging applications
to detect cancerous tissue sites.12 Tissue samples can be
measured in their native form under in vivo or ex vivo
conditions. In the latter case, snap-frozen thin sections
deposited on quartz or CaF2 slides are preferred. Therefore,
elaborate fixation and staining steps are not necessary.
The number of publications focusing on AD biomarker
detection via Raman spectroscopy in tissue samples has
increased during the last years.13−19 The focus of most of them
lies on the localization of amyloid β plaques in brain tissue of
mouse models and AD patients. Palombo et al.13 combined
immunofluorescence imaging with Fourier-transform infrared
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and Raman spectroscopy and showed that a lipid ring
surrounds the protein rich plaques. This was further supported
by two other studies based on stimulated Raman scattering
microscopy on brain tissue.16,19 In a recent report, however,
Lochocki et al.15 performed Raman imaging on postmortem
brain tissue of AD patients and found contradictory results.
Autofluorescence images performed prior to Raman measure-
ments of the investigated tissues showed uniformly distributed
bright spots that could be falsely associated with amyloid β
plaques but could not be confirmed via Thioflavin-S staining.
Instead, the bright spots were associated with lipofuscin.
Lipofuscin aggregates are formed by lipids, metals, and
misfolded proteins, containing fine yellow-brown granules,
and are linked with neuronal loss and might have an active role
in neurodegeneration.20 In the Raman maps, these regions
showed high fluorescence signals, probably caused by the
chromophores present in lipofuscin. A unique plaque-specific
spectrum could not be determined even after possible spectral
interferences were carefully removed.
The number of reported Raman studies on retina samples is
scarce.21−25 This might be due to the rapid degradation of the
retina after death and the challenges associated with in vivo
Raman measurements on the eye. The studies published by
Gellerman et al.25 on the distribution of carotenoid content in
the macula via resonance Raman spectroscopy are the only in
vivo applications reported so far. However, by using resonance
Raman spectroscopy, valuable information from a biological
material, whose signals are not enhanced, are lost. In a previous
publication, we showed that the ex vivo human retina delivers
very rich spectral information when investigated with an
excitation wavelength outside of resonances at 785 nm.21
Raman imaging provided valuable insights into the molecular
composition by probing the entire molecular fingerprint, i.e.,
the lipid, protein, carotenoid, and nucleic acid content.
Furthermore, we also showed that comparable Raman spectra
of isolated human retina can also be obtained under laser safety
regulations required for in vivo investigations.
So far, no investigations on the potential of Raman
spectroscopy to discriminate between healthy and diseased
retina samples have been conducted. In the current study,
retinas of a double transgenic mouse model (APP/PS1) that
expresses a chimeric mouse/human amyloid precursor protein
(APP; Mo/HuAPP695swe) and a mutant form of human
presenilin 1 (PS1-dE9) were subjected to ex vivo Raman
imaging. Raman maps of eye cross sections of both wild type
(WT; C57BL/6J) and APP/PS1 (AD) mouse model as well as
en face mounted isolated retinas were measured. We show that
this label-free approach provides information on the
biochemical composition of the retinal layers and can
discriminate between healthy and diseased samples with an
accuracy of 86% based on the acquired Raman spectra.
■ RESULTS AND DISCUSSION
Identification of Retinal Layers by Raman Spectros-
copy. To investigate whether the different retinal layers can be
discriminated based on distinct Raman signals, cross sections
of murine eyes collected from a WT and AD mouse have been
subjected to Raman imaging. The retina of vertebrates consists
of 10 different layers. In order to capture the layered structure
of the retina, a spatial resolution of 2 μm across the layers was
used. The inner and outer limiting membranes, however, have
a thickness smaller than 1 μm,26 and therefore, they cannot be
resolved due to the chosen measurement conditions. In Figure
1a, the Raman-based images show several layers highlighted
with different colors corresponding to five clusters obtained
after hierarchical cluster analysis (HCA), which groups the
spectra of the recorded data based on the similarity of their
spectral profile. The mean spectra for each cluster (raw and
processed) are also shown in the same figure. The black cluster
in Figure 1b contains no Raman information as the
Figure 1. Raman-based HCA cluster images (a) of a 400 × 260 μm2 region (2 μm × 5 μm pixel size) of the retina cross section of an AD mouse
(top) and a 300 × 300 μm2 region (2 μm × 10 μm pixel size) of the retina cross section of a WT mouse (bottom). The corresponding cluster
centroids are depicted as raw mean spectra (b) and background-corrected mean spectra (c) based on the HCA clusters in the same color-coding.
H&E-stained retina cross section of an AD (top) and WT (bottom) mouse (d) correlates well to the cluster images in (a).
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measurement positions were situated outside of the tissue. The
red cluster is dominated by the fluorescence emission of
chromophores, mainly melanin granules, found in the retinal
pigment epithelium (RPE) and choroid. Despite of using 785
nm as the excitation wavelength for the Raman scattering, the
detection of Raman signals from this region turned out to be
challenging. Having in mind the aimed application, in vivo
Raman spectroscopy on the human retina, two aspects
concerning fluorescence generation should be considered.
First, the RPE of mice is stronger pigmented than the one of
humans. Second, the laser focus will mainly probe the inner
layers (close to the vitreous humor) of the retina with a
thickness of around 500 μm. Therefore, under in vivo
measurement conditions, where the human retina is inves-
tigated from the front side, it is expected that significantly less
fluorescence will be induced and collected from the RPE
leading to a significantly reduced background.
An extended multiplicative scatter correction algorithm
(EMSC) was used to effectively correct for the varying
background contributions within each data set (see Chemo-
metric Analysis). The background-corrected spectra of the
three clusters rich in Raman information are plotted in Figure
1c. Raman bands typically assigned to proteins and lipids can
be seen in all three clusters, namely, the CC stretching mode
at 1657 cm−1, CH2 bending vibration at 1445 cm
−1, ring
breathing mode of phenylalanine at 1003 cm−1, and CH
stretching modes in the high wavenumber region with a
maximum at 2933 cm−1. The purple cluster corresponds to the
outer and inner segment containing rods and cones. In the case
of nocturnal animals, the photoreceptor cells are rod
dominated. Rhodopsin, the main chromophore found in
rods, is a light-sensitive receptor protein that enables vision
in low-light conditions. The bands at 1548, 1204, 1155, and
965 cm−1 are the most prominent Raman modes associated
with N−H bending, C−C, and CC stretching vibrations of
this molecule.27,28 In the case of the light blue cluster, as
compared to the two other ones, a higher nucleic acid content
can be seen due to distinctive bands at 785, 1092, and 1574
cm−1. The two layers can be assigned to the inner and outer
nuclear layer of the retina. Additionally, scattered pixels
attributed to the same cluster can be observed in the lower side
of the Raman image. This might originate from the ganglion
cells that are dispersed over the inner side of the retina and do
not form a large distinctive nuclear layer. Lastly, the dark blue
cluster can be associated with the inner and outer plexiform
layers, where a network of axons and synapses enables
communication between cells.
In routine analysis the investigation of the biochemistry of
tissue sections, such as retina, is performed via histological
analysis. To correlate the Raman cluster images, standard
hematoxylin and eosin (H&E) staining was performed on an
AD and a WT mouse eye cross section. The resulted
micrograph shows also a layered structure of the retina,
which corresponds well to the described Raman cluster images
(see Figure 1d and Figure S1 in the Supporting Information).
Staining procedures require elaborate sample preparation steps
to be carried out before the actual imaging, and detection of a
particular pathogenic factor or a biomarker expressed in a
tissue relies on antibodies with high sensitivity and specificity.
Furthermore, a series of stainings and control stainings (in
which antibodies are omitted) have to be performed to
demonstrate specificity.7 In the case of Raman imaging, sample
preparation only needs cryo-sectioning of the tissue which
significantly decreases the possibility of alterations and artifacts
caused by sample handling or the detection strategy (e.g.,
antibody or other labels). Therefore, ex vivo Raman
investigations of retina samples can be carried out label-free
and, in addition, might give significant insights into the
biochemical changes of biological tissues.
All investigated retina samples (see Figure S2 in the
Supporting Information) showed the well-known layered
structure with some spectral differences due to local
Figure 2. Bright field image (left) and Raman-based HCA cluster image (right) depicting a representative en face retina (a). Corresponding cluster
centroids are displayed as raw mean spectra (b) and background-corrected mean spectra (c) based on HCA clusters of a Raman image in the same
color coding. Only spectra from the blue cluster contain retinal Raman information.
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biochemical variations. The HCA analysis did not reveal any in
small spots concentrated cluster that could be assigned to
extracellular amyloid β aggregates. In order to get a complete
picture, Western blots were performed on homogenized retina
samples (see Supporting Information for further details) with
various amyloid β antibodies. In Figure S3, no differences
between WT and AD mice were observed regarding the
presence of the amyloid β protein. These findings are
supported by a recent study reported by the group of
Baumann,5 where retinas of APP/PS1 mice were subjected
to OCT, immunohistochemical staining and fluorescence
investigations in order to assess the diagnostic value of retinal
analysis for AD. They found that only one mouse out of 17
mice showed fluorescence signals that could be attributed to
extracellular amyloid β accumulation located ca. 15 μm below
the surface of the retina extending into the inner plexiform
layer. This particular mouse was 104 weeks old. Compared to
the present study, the Raman images presented in Figure 1
were measured on retinas of 48 week old mice. Hence, the
absence of amyloid β accumulations in the Raman images is in
line with the findings of the Baumann group.
Discrimination of Healthy vs AD Diseased Retina. As
outlined above, the development of mature AD-associated
plaques inside the mouse retina especially in early weeks is
rather unlikely. However, biochemical changes as precursors of
plaque formation might already occur. To investigate the
possibility that Raman analyses allow differentiation between
retinas from the healthy WT control mice versus AD-prone
APP/PS1 mice, en face Raman images of the entire retinas were
recorded. Instead of probing the different layers in the cross
sections, here the information on the inner layers of the retina
are gathered at once. The en face configuration was chosen
because it mimics future in vivo experiments and facilitates the
translation to settings in patients.
Figure 2a displays a bright field image of a representative en
face retina (WT) and the resulting Raman-based HCA cluster
image. As no macroscopic differences were noticed between
the bright field images of the different samples, for clarity just
one image is provided. The HCA cluster centroids are plotted
Figure 3. Overall mean spectra based on the two groups WT (red) and AD mice (black) of the en face Raman measurements used for the
classification model (a) and the cross sections (b) shown in Figure 1.
Figure 4. Trained PLS-LDA model representing the LD1 coefficients for one iteration based on the two groups (a) and in the spectral domain (b).
Prediction of the unknown spectra based on the developed model (c). ROCs of the 10-fold internal cross validation are shown in gray and their
average in black (d).
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as means without (b) and with the implemented EMSC
background correction (c) in the same color coding. The black
cluster represents the locations outside the sample and the red
cluster corresponds to areas with high fluorescence masking
any Raman information. These fluorescent areas are corre-
sponding to dark locations in the bright field image, hinting at
high pigmentation, most likely due to remains from the RPE
and choroid, which was not fully detached during the isolation.
As seen in the red spectra of Figure 2b and c, the fluorescence
is effectively filtered out by the EMSC algorithm. Only the blue
cluster shows distinct Raman bands containing retinal
information.
Each en face Raman image was processed using HCA
clustering and only spectra containing retinal Raman
information (blue cluster) were used to build the following
classification model. Figure 3a presents the mean of all spectra
used for the classification separated by the two groups; WT
control mice (red) and AD mice (black), as outlined under
Chemometric Analysis. Typical Raman bands of lipids and
proteins at 1003, 1445, and 1657 cm−1 as well as the
characteristic CH stretching region at high wavenumbers can
be seen in both spectra. Furthermore, bands corresponding to
nucleic acids around 785, 1029, and 1574 cm−1 are present,
indicating that the Raman focus reached into the nuclear layers
of the retinas. Even small contributions of Rhodopsin can be
identified at 965, 1155, 1204, and 1548 cm−1. To allow a
comparison between the en face and cross section samples, the
spectra of the cross section measurements shown in Figure 2c
were averaged and are displayed in Figure 3b. The results are
in high agreement with each other. The intensity of the
Rhodopsin signals is slightly smaller in the en face measure-
ments compared to the cross sections. Most likely, the laser
focus does not reach the entire rod-containing layer in en face
mounted samples.
Figure 3a shows that the spectra obtained by en face imaging
of the retinas from WT reference and AD mice are not
distinguishable by naked eye, which is in line with the observed
structural similarity of the cross sections of Figure 1. To detect
underlying subtle changes in the Raman profiles, a partial least
squares-linear discriminant analysis (PLS-LDA) was applied to
the data set (see Chemometric Analysis). Figure 4 represents
the results of one iteration of the 10-fold internal cross
validation. In Figure 4a each spectrum used for building the
PLS-LDA model is represented by a dot and grouped into the
two classes (AD, black; WT, red). The coefficients plotted as
LD1 determine the model-based separation of the two classes
(dotted line), which is plotted in Figure 4b in the spectral
domain. Negative features (bands) are more pronounced in
spectra corresponding to AD, while positive features
correspond to the WT group. Hence, bands at 2933, 1045,
and 450 cm−1 are more prominent in spectra of AD than of
WT and furthermore can be assigned to proteins. This
indicates an early stage biochemical change in the protein
composition that precedes the more conventional late-stage
structural changes and pathological manifestation of AD. For
the purpose of testing how well the model performs, the
recorded data set was split before modeling. The groups of the
unknown spectra were then predicted and the results are
shown in Figure 4c. Again a clear separation between the two
classes was found as most spectra were grouped in their
corresponding classes (AD, 591; WT, 580 correctly classified
out of each 693 spectra). In Figure 4d, the receiver operating
curve (ROC) is shown for the 10-fold cross validation
including the single iterations in gray and their average in
black. Due to only small variations of the ROCs between the
single iterations, it can be seen that the model is stable. In total
for all iterations, a sensitivity of 86.2% and a specificity of
85.5% were achieved. Hence, a discrimination between healthy
and AD diseased retinal tissue with the established model is
possible with an accuracy of 85.9%.
■ CONCLUSIONS
Raman spectroscopic investigations provided rich information
on the biochemistry of mouse retinas without any labeling or
sophisticated sample treatment. In an ex vivo setting, insight
into the layered structure of retina cross sections was provided
without the need of staining procedures. The layers were
identified based on their different contents of nucleic acids,
Rhodopsin, lipids, and proteins. A similar spectral profile is
recorded, when investigating en face mounted samples: a
configuration which is closer to the targeted in vivo application.
Here, the layers are recorded simultaneously, and the Raman
signals are accumulated into one spectrum. With a focus on
Alzheimer’s disease detection, the Raman signature of retinas
of AD-prone APPswe/PS 1dE9 mouse model was compared to
Raman spectra of retinas of the C57BL/6J wildtype model.
Clear amyloid beta accumulations could not be found in either
the cross sections or the en face samples, which is in line with
recently published investigations using modalities such as
OCT, fluorescence, and immunohistochemical staining.
However, subtle underlying changes in the biochemistry of
the retina could be identified by chemometric modeling. With
a sensitivity of 86.2%, spectra of AD-diseased mice were
correctly recognized as such.
■ METHODS
Materials. Biobank Tissue. Eye and brain biopsies from a mouse
tissue biobank at Radboud University Nijmegen Medical Center
(Nijmegen, The Netherlands) were used. The biobank contains tissue
from reference control groups and surplus mice of breeding. The
animals were subjected to 0.1 M PBS transcardial perfusion.
Methodological details of organ collection and processing are
provided in the paragraphs below. For the present study, we have
used tissues from APPswe/PS 1dE9 mice (AD) generated by
Jankowsky and Borchelt29 that were backcrossed on C57BL/6J
background as described in detail by Wiesmann et al.30 and respective
control tissue from wildtype C57BL/6J mice (WT). The mice brain
tissues were characterized for the presence (AD) and absence (WT)
of amyloid β1−42 immunoreactivity as detailed in Supporting
Information Figure S4. Biopsies of male and female mice were used
for this study, and all tissues were processed at TNO, Leiden, The
Netherlands.
Preparation of Cross Sections of Whole Eyes. To generate whole
eye cross sections for Raman measurements, frozen eyes stored at
−80 °C were embedded in Tissue Tek (Sakura Finetek Europe b.v.,
Alphen a/d Rijn, The Netherlands) and 10 μm sagittal slices were
made on a Leica CM1950 cryostat at TNO (Leiden, The
Netherlands). Four sections from WT and five sections from AD
mouse eye were mounted on CaF2 slides (Crystal GmbH, Berlin,
Germany) and shipped frozen on dry ice to Leibniz Institute of
Photonic Technology (Leibniz-IPHT) for Raman measurements. The
cross sections are from one female AD and one female WT mice with
an age of 48 weeks. WT and AD eyes used for whole eye cross
sections for histological staining were from male mice with an age of
38 weeks.
Preparation of En Face Samples. For en face Raman measure-
ments, left and/or right eyes from 10 AD mice and 10 WT mice were
used. This allowed isolation of 15 AD and 15 WT retinas suitable for
Raman imaging. The age of the mice used for en face Raman analyses
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was 12 months. Eyes were carefully thawed in 4 °C cold 1× PBS for
the duration of 1 h and afterward transferred onto a gauze soaked in
cold 1× PBS in a Petri dish. The cornea was removed by an incision at
the limbus into the anterior chamber. Scissors were then inserted into
the anterior chamber and circumferential cuts were made in the
cornea, just anterior to the limbus, to remove the lens and iris. The
eye was opened up with four equally spaced cuts from the ciliary body
toward the optic nerve head. The vitreous was removed, and the
retina was carefully lifted with forceps and placed on CaF2 slides, on
which the retina was immediately frozen using dry ice. The entire
isolation procedure took approximately 10 min. Sample remained
frozen and were shipped on dry ice to the Leibniz-IPHT in Jena,
Germany for Raman analysis.
Methods. Histological Staining of Tissues to Characterize
Tissue Biopsies. After enucleation, whole eyes were fixated in 10%
buffered formalin for 24 h. Hereafter, eyes were transferred to PBS
containing NaN2 (0.02%) and stored at 4 °C until use. Prior to
sectioning, the eyes were embedded in paraffin and 5 μm sagittal
sections were made for H&E staining. Digital images of H&E
stainings were captured using an Olympus BX51 microscope with an
Olympus DP74 camera with 20× magnification.
Raman Spectroscopic Measurements. After drying under ambient
conditions, Raman images of the isolated retina samples (cross section
and en face) were recorded with a confocal Raman microscope
alpha300 R (WITec, Ulm, Germany) equipped with a diode laser
providing an excitation wavelength of 785 nm (Toptica Photonics,
Graf̈elingen, Germany) with a laser power set to 20 mW at the sample
plane. A 300 g/mm grating covered the complete wavenumber region
from 100 to 3300 cm−1 with a spectral resolution of around 6 cm−1.
Raman images of retina cross sections were recorded with 3 s
integration time using a 50× Zeiss objective with NA 0.9. Several
regions were selected on two cross sections for each mouse type.
Across the retinal layers a step size of 2 μm and along the layers a step
size of 5 or 10 μm was used (see details in the Supporting
Information, Table S1). Raman spectra of en face retina samples were
recorded with 5 s integration time with a previous 3 s prebleaching
time to reduce high fluorescence background occurring at locations in
the retina, at which the highly pigmented RPE layer and choroid were
not completely separated from the isolated retina. A 10× Olympus
objective with NA 0.25 was used, and a step size of 50 or 75 μm,
depending on the total sample size, was chosen to image the entire
retina.
Chemometric Analysis. Data processing was performed in R31
using hyperSpec32 as a main package. Preprocessing of the spectra
included wavenumber calibration with paracetamol as a reference, a
wavenumber interpolation step, background correction using the
EMSC, and cosmic spike correction.33 The EMSC is based on least-
squares fitting of single spectra against user-defined spectral profiles
including background and pure component spectra, where sub-
sequently the background contributions are subtracted from the raw
single spectra. Here, two estimated fluorescence profiles were
included as background components, additional to a linear function
and an offset. A well-corrected spectrum of an en face retina sample
was used as a pure component. The wavenumber range from 400 to
3200 cm−1 was used for analysis. Subsequently, each Raman image
was subjected to a HCA algorithm to group the spectra into clusters
of the same spectral profile using a Pearson distance calculation and
Ward clustering algorithm. The resulting cluster centroids represent
weighted average spectra for each cluster and in a false-color
representation the spectral differences in the Raman image are
visualized. A PLS-LDA was used to build a classification model for the
discrimination of healthy (WT) vs AD diseased tissue based on the en
face retina samples. In total, three batches with each five diseased
(AD) and five control (WT) eyes were prepared. Only the spectra of
the HCA clusters containing retinal information were included to the
model. An area normalization to the high wavenumber region
between 2800 and 3100 cm−1 and a quality control based on a
correlation function with a threshold at 0.95 to remove outliers and
spectra with low SNR were performed resulting in 6930 AD and
12 253 WT spectra. The reduced number of spectra from the AD
model is for once due to samples being smaller in size and due to a
higher amount of fluorescence contribution compared to the WT
model. Smoothing of the spectra was performed using a Fourier
transformation technique. For modeling, the number of healthy retina
spectra was randomly sampled so that the two groups are equal in
size. As an external cross validation, the random sampling was
performed 10 times. For each iteration, the equalized data set of WT
and AD spectra was split in 10 equal folds, where 9 folds were used to
train the model and the remaining fold to predict the classes of the
spectra. Each fold was once used for prediction. To evaluate the
performance of the model, ROCs of the 10-fold iterations were
calculated based on the true positive versus the false positive rate by
using the R package ROCR.34
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